26 results about "Umbilical vein" patented technology

The invention discloses a combined evaluation method for in-vitro and in-vivo red fading and relieving effects of cosmetic raw materials, which comprises the following steps: in-vitro model evaluation: inducing a human immortalized umbilical vein endothelial cell model by adopting TNF-alpha, and detecting the secretion amount of a prostacyclin I2 factor to obtain a score of an in-vitro model; in-vivo model evaluation: adopting a chick embryo chorioallantoic membrane model, and obtaining a score of the in-vivo model according to the degree of vasoconstriction caused by the to-be-detected raw material sample acting on the chick embryo chorioallantoic membrane; and comprehensive evaluation: based on the score of the in-vitro model and the score of the in-vivo model, comprehensively evaluating the red fading and relieving efficacy of the raw material sample to be tested. According to the technical scheme, the defect that in the prior art, no cosmetic raw material soothing efficacy evaluation method for the vascular reactivity increasing mechanism exists is overcome, efficacy evaluation is more accurate, the method has the advantages of being comprehensive, short in test period, easy to operate, economical and convenient, and an effective reference basis is provided for screening and compounding schemes of red fading and soothing raw materials.

The invention belongs to the field of organic synthesis and medicinal chemistry, and particularly provides an efficient synthesis method of an N, N-diphenyl aniline compound based on a naphtho-indolizino-phenothiazine skeleton and anti-tumor application of the N, N-diphenyl aniline compound based on the naphtho-indolizino-phenothiazine skeleton. Through Suzuki reaction, functional coupling based on a naphtho-indolizino-phenothiazine skeleton and an N, N-diphenyl aniline group is realized for the first time. In-vitro anti-tumor evaluation shows that the compound has remarkable inhibitory activity on various human tumor cells, especially has the strongest effect on breast cancer MCF-7 cells (IC50 = 0.15 mu M), and the activity is improved by 266 times compared with that of cis-platinum; prostate cancer PC-3, liver cancer HepG2, lung adenocarcinoma A549 and cervical cancer Hela cells are also remarkably inhibited. The toxicity to normal umbilical vein endothelial cells (HUVEC) is far lower than that of tumor cells, and the selectivity is excellent. The research provides a lead compound with great potential for developing high-efficiency and low-toxicity targeted anti-tumor drugs.

The anti-falling umbilical vein catheter comprises an umbilical vein catheter body with the inner end inserted into the body, a first buckle is embedded in the portion, located outside the body and close to the umbilical region, of the umbilical vein catheter body in a clamped mode, the first buckle is attached to the surface of the skin, and the first buckle and the skin are connected and fixed through a silk thread. A sterile gauze covering the umbilical vein catheter and the first buckle is laid on the abdomen of the child patient, a circle of wide bellyband is wound around the abdomen of the child patient and attached to the sterile gauze, a second buckle located on one side of the abdomen of the child patient is attached to the bottom of the wide bellyband in a pressing mode, and meanwhile the outer end of the umbilical vein catheter sequentially penetrates through the first buckle and the second buckle. When the wide-body bellyband is used, in order to prevent the umbilical vein catheter from falling off when the wide-body bellyband is loosened, the two connecting bands are arranged at the connecting end of the bellyband, in the dressing changing process, the half-winding section of the catheter can be temporarily transferred to the bottom of the connecting band which is not loosened, and the wide-body bellyband can further position and stabilize the sterile gauze.

The invention discloses a postpartum placenta blood vessel developing kit. The postpartum placenta blood vessel developing kit comprises polypropylene watercolor powder which is pre-packaged in a vacuum bottle and has the particle size of 100-300nm; the bagged normal saline is uniformly mixed with the polypropylene watercolor powder to form a polypropylene-based main developing agent; the blood vessel lock catch is used for clamping and closing the blood vessel and preventing the polypropylene-based main developing agent from flowing back through the umbilical cord blood vessel; the injector is used for respectively injecting the polypropylene-based main developing agent into the umbilical artery and the umbilical vein; the graduated scale is used for measuring the size of the placenta. By pre-preparing the dye, uniform concentration, sterility, reliability and simplicity and convenience in operation are ensured; the dye particle size can be controlled to avoid capillary blockage, and the developing quality is improved; the method can also meet diversified clinical requirements of multi-fetal, radiography verification, anticoagulation pretreatment and the like.

The invention belongs to the technical field of biological materials, and particularly relates to a rosa roxburghii tratt exosome microneedle patch for promoting skin wound healing and a preparation method of the rosa roxburghii tratt exosome microneedle patch. The roxburgh rose exosome microneedle patch for promoting skin wound healing comprises a patch base body and a microneedle array which are integrally formed, the microneedle array is distributed on the surface of the patch base body, and the patch base body and the microneedle array are made of degradable materials doped with roxburgh rose exosomes; after penetrating through a skin barrier, constructing a roxburgh rose exosome delivery channel and degrading, the roxburgh rose exosome can be uniformly released to a skin wound to accelerate migration of human immortalized keratinocytes, fibroblasts, human umbilical vein endothelium and other cells so as to promote repair and healing of skin tissues such as epidermis, dermis and subcutaneous tissues; according to the application, the application range of the roxburgh rose exosome is expanded, the roxburgh rose exosome is effectively utilized, and the technical problems that the efficacy of the roxburgh rose exosome is lack of research and the roxburgh rose exosome is difficult to effectively apply at present are solved.

The invention belongs to the technical field of bioengineering, and particularly relates to application of rRF-36 in screening of drugs for treating or preventing atherosclerosis. The sequence of the rRF-36 is as shown in SEQ ID NO. 1. A carotid artery ligation model is constructed through APOE mouse partial carotid artery ligation, and compared with a control group, in-vivo rRF-36 after mouse carotid artery ligation is remarkably reduced. A further research finds that after the vascular endothelial cells are stimulated by low-oscillation shear stress, the rRF-36 is also remarkably reduced. Therefore, an rRF-36 overexpression primer si-Mimics is designed, and the si-Mimics is found to be capable of reversing endothelial-mesenchymal transformation induced by low-oscillation shear stress, which indicates that the gene rRF-36 can regulate and control coronary atherosclerosis caused by endothelial-mesenchymal transformation of umbilical vein endothelial cells.

The invention discloses an ultrasonic imaging method and an ultrasonic imaging system for a fetus in the middle-late pregnancy period. The method comprises the following steps: S220, obtaining three-dimensional ultrasonic data of the fetus in the middle-late pregnancy period; s230, according to the three-dimensional ultrasonic data, the long axis direction of the body area of the fetus in the middle-late pregnancy period is determined; s540, extracting information of a mid-late pregnancy target feature structure of the fetus from the three-dimensional ultrasonic data, wherein the mid-late pregnancy target feature structure comprises at least one of the following parts: gastric vesicle, spine bone, liver, umbilical vein, descending aorta, inferior vena cava, umbilical cord insertion position, umbilical cord, anterior abdominal wall, bladder, legs, umbilical artery and gallbladder; and S560, extracting at least one abdominal standard section of the fetus in the middle-late pregnancy period from the three-dimensional ultrasonic data according to the information of the long axis direction and the middle-late pregnancy target feature structure, and displaying the extracted abdominal standard section. According to the ultrasonic imaging method and the ultrasonic imaging system, the abdominal standard sections of the fetuses in the middle-late pregnancy period are automatically extracted according to the three-dimensional ultrasonic data collected at a time, a doctor does not need to manually extract the abdominal standard sections one by one, and the efficiency of extracting the abdominal standard sections and the quality of the extracted abdominal standard sections are improved.

The invention discloses a construction method and application of a kidney cell co-culture microsphere model, and belongs to the technical field of cell culture. According to the method, an in-vitro model closer to in-vivo physiological characteristics is successfully constructed by optimizing the proportion and the initial balling amount of three cells with different physiological functions, and the method comprises the following steps: human renal cortex proximal tubule epithelial cells HK-2, human embryo kidney cells HEK293T, human kidney cells HEK293T, human kidney cells HEK293T, human kidney cells HEK293T, human kidney cells HEK293T and human kidney cells HEK293T are preparing a mixed cell suspension from human umbilical vein fusion cells EA.hy926 according to a ratio of 4: 1: 1 and an initial balling amount of 1500 cells; inoculating to a 96-hole ultra-low adsorption culture plate, and carrying out three-dimensional self-assembly culture for 48 hours to finally form a kidney microsphere model with a space structure; the model disclosed by the invention is closer to a cell environment in a human body, and has important application value in the aspects of toxin safety evaluation and kidney disease mechanism research.

The invention discloses a PINK1 inducible expression cell line of a porcine umbilical vein endothelial cell and a construction method and application thereof, a stable cell line with controllable PINK1 expression level is constructed by introducing a porcine PINK1 gene into the porcine umbilical vein endothelial cell and combining with an inducible expression system taking doxycycline as an inducer. The cell line is in a low-expression or non-expression state under the condition that an inducer is not added, and dose-dependent induced expression can be realized after doxycycline is added. Experimental results show that the induced expression of PINK1 can regulate and control the expression of angiogenesis related genes, activate mitochondrial autophagy related pathways under oxidative stress conditions, and influence the expression of cell proliferation and apoptosis related proteins at the same time. The cell line is clear in construction method and good in stability, can be used as an in-vitro model for researching angiogenesis, oxidative stress and related regulation and control mechanisms of porcine vascular endothelial cells, and has good practical value.

A method for neonatal monitoring includes catheterizing a neonatal patient via an implanted umbilical interface, infusing a signaling fluid into the neonatal patient via the neonatal PiCCO venous catheter, monitoring circulating blood for a hemodynamic signal via the neonatal PiCCO arterial catheter, and detecting the hemodynamic signal. Catheterizing the neonatal patient via the implanted umbilical interface includes inserting the neonatal PiCCO arterial catheter into an umbilical artery of the neonatal patient and inserting the neonatal PiCCO venous catheter into an umbilical vein of the neonatal patient.

The invention belongs to the technical field of animal models, and particularly relates to an ECMO-removed artificial uterine animal model and a construction method thereof. The animal model comprises an animal maternal body, an in-vitro fetus and an artificial uterus, the fetus is from the animal maternal body, blood circulation is established between the animal maternal body and the fetus, the blood circulation starts from the internal carotid artery of the animal maternal body, is connected to the umbilical vein of the fetus through a pipeline and enters the body of the fetus, and after the fetal circulation, the artificial uterus enters the fetal body. Starting from the fetal umbilical artery, entering the internal jugular vein of the animal maternal body through a pipeline; the fetus is located in the artificial uterus, and the artificial uterus provides a sterile artificial amniotic fluid environment for the fetus and maintains the body temperature of the fetus. According to the method, the ECMO-removed artificial uterine animal model is successfully constructed through the pregnant sheep, and the ECMO-removed artificial uterine animal model is maintained for about 90 minutes at most. A feasible animal model is provided for early surgical treatment of fetal congenital diseases and life maintenance of premature fetuses, and a foundation is laid for future clinical transformation.

The invention relates to the technical field of biological medicines, and particularly discloses application of a product for promoting WBP11 gene expression in preparation of a medicine for treating or preventing bronchial pulmonary dysplasia. The product for promoting WBP11 gene expression promotes proliferation of human primary umbilical vein endothelial cells by promoting WBP11 gene expression, and promotes the tube forming ability of the human primary umbilical vein endothelial cells in bronchial pulmonary dysplasia.

The present invention discloses a sheep umbilical cord and placenta development promoting feed, which comprises a TMR daily ration and rumen bypass coated folic acid, and the addition amount of the rumen bypass coated folic acid in each kilogram of feed dry matter is 16 mg. The invention relates to the field of animal nutriology and embryology, aims to improve the survival rate and growth performance of fetuses, and specifically comprises the following steps: adding rumen bypass coated folic acid of a specific dose into daily ration of pregnant sheep, and continuously feeding the pregnant sheep from mating to lambing. According to the method, the fetal umbilical cord diameter can be remarkably increased, the sheep umbilical vein cross section area can be improved, the nutrient substance transportation capability of the umbilical cord can be enhanced, the placenta structure and function can be improved, the placenta trophoblast cell density can be improved, and the maternal-fetal nutrient substance transmission efficiency can be enhanced. The method has the advantages of simplicity and convenience in operation, remarkable economic benefit and the like.

The utility model provides an umbilical vein fixing clamp which comprises fixing clamp bodies, tightening springs, connecting extension seats, a supporting bypass, an umbilical vein indwelling catheter and a protective pad, the tightening springs are fixedly installed in the fixing clamp bodies, and the connecting extension seats are fixedly installed above the tail portions of the two fixing clamp bodies respectively. The supporting bridge is fixedly mounted above the two groups of connecting extension seats; the umbilical vein indwelling catheter is arranged on the supporting bypass, and the protective pad is adhered to the bottoms of the two groups of fixing clamps; due to the arrangement of the fixing clamp, the supporting bridge and the protective pad, the skin of a baby cannot be injured, the nursing workload is greatly reduced, and the fixing effect is stable.

The invention relates to the technical field of nano medicine, in particular to mesenchymal stem cells modified by a nucleic acid nano material as well as a preparation method and application of the mesenchymal stem cells. According to the invention, a DNA structure containing an initiation chain of a hybridization chain reaction is modified on the mesenchymal stem cell through a nucleic acid nanotechnology, and a large number of adhesion promoting functional groups and angiogenesis promoting functional groups are modified on the mesenchymal stem cell through the hybridization chain reaction, so that the mesenchymal stem cell modified by a nucleic acid nanomaterial is obtained. According to the mesenchymal stem cell modified by the nucleic acid nanomaterial, on the cellular level, the anti-oxidative stress capacity of the mesenchymal stem cell can be improved, the cell activity can be obviously improved, the adhesion capacity of the mesenchymal stem cell to umbilical vein endothelial cells is promoted, and the repairing capacity and the cell activity of the umbilical vein endothelial cells are promoted. And on the living body level, the implantation rate of the mesenchymal stem cells in the wound part can be improved, the angiogenesis of the wound part is promoted, and the wound repair speed is accelerated.

The application discloses a combined evaluation method for the in-vitro and in-vivo redness-reducing soothing effect of a cosmetic raw material, which comprises in-vitro model evaluation, adoption of a human immortalized umbilical vein endothelial cell model induced by TNF-alpha, acquisition of the in-vitro model score by detecting the secretion amount of prostacyclin I2 factor, in-vivo model evaluation, adoption of a chicken embryo chorioallantoic membrane model, acquisition of the in-vivo model score by the degree of blood vessel contraction caused by the action of the sample to be tested on the chicken embryo chorioallantoic membrane, and comprehensive evaluation of the redness-reducing soothing effect of the sample to be tested based on the in-vitro model score and the in-vivo model score. The technical scheme of the application makes up for the defect of the prior art that there is no cosmetic raw material soothing effect evaluation method for the mechanism of increased vascular reactivity, the effect evaluation is more accurate, and the method has the advantages of comprehensiveness, short test cycle, simple operation, economy and convenience, and provides an effective reference for the screening and compounding scheme of redness-reducing soothing raw materials.

A method and system for ultrasound imaging of a mid- to late-trimester fetus includes the following steps: (S220) obtaining three-dimensional ultrasound data of a mid- to late-trimester fetus; (S230) determining the longitudinal direction of a body region of the mid- to late-trimester fetus based on the three-dimensional ultrasound data; (S540) extracting information on target characteristic structures of the mid- to late-trimester fetus from the three-dimensional ultrasound data, wherein the target characteristic structures include at least one of the following: gastric alveoli, spinal column, liver, umbilical vein, descending aorta, inferior vena cava, umbilical cord insertion, umbilical cord, anterior abdominal wall, bladder, legs, umbilical artery, and gallbladder; and (S560) extracting and displaying at least one standard abdominal section of the mid- to late-trimester fetus from the three-dimensional ultrasound data based on the longitudinal direction and the information on the target characteristic structures. The method and system automatically extract standard abdominal sections of the mid- to late-trimester fetus from a single acquisition of three-dimensional ultrasound data, eliminating the need for a doctor to manually extract standard abdominal sections one by one, thereby improving the efficiency and quality of the extracted standard abdominal sections.

The present invention relates to the technical field of medical instruments. Provided are a sequential balloon pulsatile blood pump for an artificial uterus, and a system and a method. The blood pump comprises: a pump body, which is arranged in a blood flow circuit of an artificial placenta and comprises a first pump chamber and a second pump chamber, wherein the first pump chamber and the second pump chamber are connected in parallel by means of a conduit, and two ends of the conduit are respectively an inlet end and an outlet end of blood, the inlet end being in communication with an umbilical artery of a fetus, and the outlet end being in communication with an umbilical vein of the fetus by means of an oxygenator; a controller, which is in communication connection with both a first air pouch assembly and a second air pouch assembly; and a heart acquisition unit, which is arranged on the outer surface of an artificial uterus and is in communication connection with the controller. The present invention has advantages, such as being capable of generating a pulsating blood flow, adapting to the high heart rate of a fetus, not affecting a cardiac afterload balance of the fetus, and preventing umbilical vascular intubation spasm.

A method for neonatal monitoring includes: catheter insertion into a neonatal patient through an implanted umbilical interface; injecting a signal fluid into the body of the neonatal patient through the neonatal PiCCO venous catheter; monitoring hemodynamic signals of circulating blood through a newborn PiCCO arterial duct; and detecting the hemodynamic signal. Catheter insertion into a neonatal patient through an implanted umbilical interface includes: inserting a neonatal PiCCO arterial catheter into an umbilical artery of the neonatal patient; and inserting the neonatal PiCCO venous catheter into the umbilical vein of the neonatal patient.

The invention provides application of an FGF5 gene inhibitor in preparation of anti-tumor angiogenesis drugs, and belongs to the technical field of biological medicines. The invention provides application of a reagent for inhibiting expression of an FGF5 coding gene or a reagent for inhibiting expression or functions of FGF5 in preparation of anti-tumor angiogenesis drugs. In the invention, tumor angiogenesis can be inhibited by inhibiting expression of FGF5. Results of the embodiment of the invention show that overexpression of the FGF5 protein and the coding gene thereof can effectively promote migration and invasion of human umbilical veins and tubule formation, and knock-down of expression of the FGF5 inhibits migration and invasion ability of the human umbilical veins and tubule formation ability. A subcutaneous tumor generation experiment further verifies that the FGF5 can promote the growth of a subcutaneous tumor HGC27 of a nude mouse, and promote tumor angiogenesis and tumor endothelial cell proliferation and migration.

The invention belongs to the field of micro-fluidic chips, and discloses a method capable of simulating cytokine storm caused by septicopyemia and determining specific cytokines. The human primary umbilical vein endothelial cell experiment is adopted, the natural characteristics of endothelial cells are reserved, and the kit is sensitive to various inflammatory factors, drugs and stimulus reactions, is closer to the real in-vivo environment, is widely applied to drug screening, therapeutic effect research and biological agent testing, and provides data with more biological significance for septicopyemia diseases. According to the method capable of simulating the cytokine storm model caused by septicopyemia, key factor screening scientificity is high, concentration setting conforms to the pathological level, and the authenticity is enhanced through the LPS synergistic effect. According to the method for specifically removing the cytokines, a specific removal strategy which is difficult to realize clinically is simulated, and the technical problem that various inflammatory factors in the body of a sepsis patient exist at the same time and interact with one another, and respective functional contributions are difficult to distinguish is solved.

The invention belongs to the technical field of diagnosis and treatment of diabetic complications, and discloses an auxiliary diagnosis and treatment method for cardiovascular complications of gestational diabetes mellitus, which comprises the following steps: S1, collecting an umbilical vein endothelial cell sample of a gestational diabetes mellitus patient; s2, detecting the expression level of miR-584-5p in the umbilical vein endothelial cell sample and the expression levels of the PTEN gene and the downstream PINK1 protein thereof, and detecting related indexes of mitochondrial autophagy at the same time; s3, in combination with clinical indexes, based on the expression level of miR-584-5p, the expression levels of the PTEN gene and the downstream PINK1 protein thereof and related indexes, evaluating the occurrence risk of the cardiovascular complications of the offspring of the gestational diabetes mellitus patient. The application provides molecular evidence for early discovery of endothelial cell dysfunction, and assists in assessment of cardiovascular complication risk of patients.

The application discloses an anti-vascular composite gene vector and a preparation method and application thereof. The anti-vascular composite gene vector is prepared by coating the cationized tussah silk fibroin which is modified by an angiogenesis inhibitor, endostatin, on the surface of an adenovirus by electrostatic adsorption. The anti-vascular composite gene vector is in the form of spherical nano-particles, can effectively infect umbilical vein endothelial cells and liver cancer cells, express anticancer genes, inhibit the proliferation of vascular endothelial cells and tumor cells, and block the growth and metastasis of tumors. Different anticancer genes are coded in the vector, so that the anti-vascular composite gene vector can play the therapeutic effect of resisting tumors and preventing metastasis for different malignant tumors. Therefore, the anti-vascular composite gene vector can be used for preparing a medicine for treating tumors.

The invention relates to the technical field of function testing of cosmetic raw materials, and particularly discloses a method and a model for evaluating in-vitro red fading and relieving effects of cosmetic raw materials, and the method comprises the following steps: inducing human immortalized umbilical vein vascular endothelial cells by adopting a TNF-alpha inducer to establish a red fading and relieving in-vitro model; the method specifically comprises the following steps: after inoculating and culturing human immortalized umbilical vein vascular endothelial cells, setting a control group, a modeling group, a positive drug group and a sample group, respectively adding special culture mediums into the control group and the modeling group, adding an epoxidase inhibitor into the positive drug group, adding a raw material sample to be detected into the sample group, and pre-treating; then adding a TNF-alpha inducer into each group except the control group, and carrying out induction culture; the prostacyclin I2 factor is adopted as a detection index to evaluate the red fading and relieving effects of the raw material sample to be detected. The method is short in test period, simple to operate, economical and convenient, and provides reliable data for further research of efficacy verification in the cosmetic industry.

The utility model relates to an auxiliary device for separating umbilical vein endothelial cells, which relates to the technical field of medical instruments, is arranged in a blood vessel of an umbilical vein in a penetrating manner, and comprises a needle-tube-shaped guide head and a hollow filling bag connected to one end of the guide head, the filling bag comprises a plurality of supporting pipes distributed in the circumferential direction, a first connecting piece and a second connecting piece, the first connecting piece and the second connecting piece are symmetrically arranged at the two ends of the supporting pipes, the end, away from the supporting pipes, of the first connecting piece is fixedly connected with the guiding head, and a liquid injection hole is formed in the end, away from the supporting pipes, of the second connecting piece in a penetrating mode. A mounting ring is arranged at the end, away from the supporting pipe, of the second connecting piece at the liquid injection hole, the inner diameter of the mounting ring is equal to the diameter of the liquid injection hole, and the mounting ring is sleeved with a needle of an injector. The quantitative digestive juice injection device has the advantages of being suitable for various injectors, capable of quantitatively injecting digestive juice, capable of providing data support for later experiments, easy to operate and not prone to liquid leakage.

The invention discloses a method for primary extraction and culture of rat umbilical vein endothelial cells, and belongs to the technical field of biology. The invention provides a primary extraction and culture method for umbilical vein endothelial cells of rats in order to solve the technical problems of relatively low extraction efficiency and relatively low cell activity of a primary extraction and culture method for umbilical vein endothelial cells in the prior art. Treating the cells by using a differential adhesion method, adding a VEGF culture medium, adding an antioxidant in primary culture, and culturing the cells in a hypoxia simulated physiological environment; therefore, digestion time is shortened, quality and purity of umbilical vein endothelial cells are improved, cell adherence and proliferation characteristics are maintained, cell aging is delayed, cell activity is improved, oxidative stress damage of cells is reduced, and cell functions are improved.